What 11 Analyst Ratings Have To Say About Avadel Pharmaceuticals
Portfolio Pulse from Benzinga Insights
11 analysts have provided ratings for Avadel Pharmaceuticals (NASDAQ:AVDL) in the last quarter, with an average price target of $16.5, implying an upside from the current price of $13.49. The average price target has increased by 10.52% over the past month.
May 30, 2023 | 8:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avadel Pharmaceuticals (NASDAQ:AVDL) has received 11 analyst ratings in the last quarter, with an average price target of $16.5, indicating an upside from the current price of $13.49.
The 11 analyst ratings for Avadel Pharmaceuticals in the last quarter are mostly bullish, with an average price target of $16.5, which is higher than the current price of $13.49. This indicates a potential upside for the stock in the short term. The average price target has also increased by 10.52% over the past month, showing growing optimism among analysts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100